ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2010-06-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 52
- Registration Number
- NCT01028950
A Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01023945
A Clinical Pharmacological Study of YM155 After Intravenous Infusion in Patients With Advanced Cancer
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2010-04-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 6
- Registration Number
- NCT01023386
A Study to Compare Safety and Efficacy of Prograf + Myfortic and Advagraf + Myfortic in Liver Transplantation Patients
Phase 4
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 44
- Registration Number
- NCT01018914
A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis
Phase 3
Completed
- Conditions
- Renal DialysisRenal InsufficiencyChronic Kidney Disease
- Interventions
- Drug: ASP1585
- First Posted Date
- 2009-11-20
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 35
- Registration Number
- NCT01017276
A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
Phase 1
Terminated
- Conditions
- CarcinomaOvarian CancerOvarian DiseasesOvarian Neoplasms
- Interventions
- First Posted Date
- 2009-11-18
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 4
- Registration Number
- NCT01016054
Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers
Phase 1
Completed
- Conditions
- Bioavailability of Solifenacin SuccinatePharmacokinetics of Solifenacin SuccinateHealthy Volunteers
- Interventions
- First Posted Date
- 2009-11-17
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01015040
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
Phase 3
Completed
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 893
- Registration Number
- NCT01011205
- Locations
- 🇫🇮
026, Helsinki, Finland
🇧🇾146, Minsk, Belarus
🇧🇪006, Gent, Belgium
A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 64
- Registration Number
- NCT01009775
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸University of South Alabama, Mobile, Alabama, United States
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment
- First Posted Date
- 2009-11-04
- Last Posted Date
- 2015-10-19
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 43
- Registration Number
- NCT01007292
- Locations
- 🇫🇷
Site FR1926 Institut Bergonie, Bordeaux-cedex, France
🇫🇷Site FR2700 Centre Antoine Lacassagne, Nice, France
🇫🇷Site FR1897 Hopital Bretonneau, Tours, France
© Copyright 2025. All Rights Reserved by MedPath